# MIRM catalysts: Mirum Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mirm/catalysts

> Mirum Pharmaceuticals, Inc. (MIRM) has 19 upcoming catalysts. The next is the volixibat topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MIRM?

Mirum Pharmaceuticals, Inc. (MIRM) has 19 upcoming catalysts. The next is the volixibat topline data readout, Q1 2027. SEC Form 8-K: "The Company also now expects topline data from its VANTAGE Phase 2b study of volixibat in primary biliary cholangitis ("PBC") in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/mirm/catalysts)

Source: SEC Form 8-K, accession 0001193125-26-202609, https://www.sec.gov/Archives/edgar/data/1759425/000119312526202609/d150234d8k.htm (retrieved 2026-11-12). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/companies/mirm/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Mirum Pharmaceuticals, Inc. |
| Ticker | MIRM (Nasdaq) |
| SEC CIK | 1759425 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mirm |

## Cash runway

Cash $500.5M as of 2026-09-30; quarterly burn $4.3M; about 348.3 months of runway at that rate (XBRL company facts, accession 0001759425-26-000062).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 29, 2021 | [LIVMARLI® (maralixibat) FDA approval](https://sec-api.dev/pdufa/maralixibat) | MIRM |  | completed, approved | "NDA214662 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210929, review_priority PRIORITY; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214662%22)) |
| March 13, 2023 | [LIVMARLI® (maralixibat) label expansion decision](https://sec-api.dev/pdufa/maralixibat) | MIRM |  | completed, approved | "NDA214662 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20230313, review_priority PRIORITY; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214662%22)) |
| Oct 2023 | [Chenodal (chenodal) topline data readout](https://sec-api.dev/pdufa/chenodal) | MIRM |  | completed, positive | "In October 2023, we reported positive topline data from our RESTORE clinical trial evaluating Chenodal in patients with CTX and we submitted a new drug application ("NDA") for chenodiol for the treatment of CTX to the FDA in June 2024, which application has been assigned a Prescription Drug User Fee Act ("PDUFA") date of December 28, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1759425/000175942524000038/mirm-20240930.htm)) |
| Oct 2023 | [Chenodal (chenodal) NDA/BLA submission](https://sec-api.dev/pdufa/chenodal) | MIRM |  | completed | "In October 2023, we reported positive topline data from our RESTORE clinical trial evaluating Chenodal in patients with CTX and we submitted a new drug application ("NDA") for chenodiol for the treatment of CTX to the FDA in June 2024, which application has been assigned a Prescription Drug User Fee Act ("PDUFA") date of December 28, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1759425/000175942524000038/mirm-20240930.htm)) |
| March 13, 2024 | [LIVMARLI® (maralixibat) label expansion decision](https://sec-api.dev/pdufa/maralixibat) | MIRM |  | completed, approved | "NDA214662 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240313, review_priority STANDARD; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214662%22)) |
| Jun 2024 | [Mirum Pharmaceuticals, Inc. interim data readout](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed, met | "In June 2024, Mirum announced positive interim results from the Phase 2b VANTAGE study showing statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and improvements in fatigue for patients treated with volixibat." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000010/mirm-20260225xexx991.htm)) |
| Jun 2024 | [Chenodal (chenodal) NDA/BLA acceptance](https://sec-api.dev/pdufa/chenodal) | MIRM | CTX, known | completed | "We announced topline results of a Phase 3 clinical trial to evaluate the effects of Chenodal in patients with CTX, known as the RESTORE clinical trial, which we used to support our NDA submission in June 2024 for marketing authorization of Chenodal for CTX in the U.S. The FDA has accepted the NDA submission and has assigned a PDUFA date of December 28, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1759425/000175942524000038/mirm-20240930.htm)) |
| July 24, 2024 | [LIVMARLI® (maralixibat) label expansion decision](https://sec-api.dev/pdufa/maralixibat) | MIRM |  | completed, approved | "NDA214662 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20240724, review_priority STANDARD; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214662%22)) |
| November 12, 2024 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/mirm-20241112xexx991.htm)) |
| December 28, 2024 | [CTEXLI® (chenodiol) PDUFA date](https://sec-api.dev/pdufa/chenodiol) | MIRM | CTX, known | scheduled | "•PDUFA date for chenodiol in CTX is December 28, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/mirm-20241112xexx991.htm)) |
| February 21, 2025 | [CTEXLI® (chenodiol) FDA approval](https://sec-api.dev/pdufa/chenodiol) | MIRM | CTX in adults | completed, approved | "NDA219488 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250221, review_priority PRIORITY; sponsor_name MIRUM; product CTEXLI (CHENODIOL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219488%22)) |
| February 26, 2025 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000012/mirm-20250226xexx991.htm)) |
| March 28, 2025 | [CTEXLI® (chenodiol) PDUFA date](https://sec-api.dev/pdufa/chenodiol) | MIRM |  | completed, approved | "•FDA Prescription Drug User Fee Act (PDUFA) date for chenodiol in cerebrotendinous xanthomatosis (CTX) is March 28, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/mirm-20250113xexx991.htm)) |
| April 10, 2025 | [LIVMARLI® (maralixibat) FDA approval](https://sec-api.dev/pdufa/maralixibat) | MIRM |  | completed, approved | "NDA219485 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250410, review_priority STANDARD; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219485%22)) |
| May 7, 2025 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000030/mirm-20250507xexx991.htm)) |
| 2H 2025 | [Volixibat topline data readout](https://sec-api.dev/pdufa/volixibat) | MIRM |  | scheduled | "•VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000012/mirm-20250226xexx991.htm)) |
| August 6, 2025 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/mirm-20250806xexx991.htm)) |
| Q4 2025 | [MRM-3379 trial start](https://sec-api.dev/pdufa/mrm-3379) | MIRM | Fragile-X Syndrome | scheduled | "•Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/mirm-20250806xexx991.htm)) |
| November 4, 2025 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/mirm-20251104xexx991.htm)) |
| February 20, 2026 | [Volixibat primary completion](https://sec-api.dev/pdufa/volixibat) | MIRM | Primary Sclerosing Cholangitis | completed | "NCT04663308 (A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-20 (ACTUAL); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04663308)) |
| February 25, 2026 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000010/mirm-20260225xexx991.htm)) |
| Q2 2026 | [Volixibat topline data readout](https://sec-api.dev/pdufa/volixibat) | MIRM | primary sclerosing cholangitis | scheduled | "The Company anticipates receipt of top-line data from the VISTAS Phase 2b clinical trial of volixibat for the treatment of primary sclerosing cholangitis ("PSC") in the second quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1759425/000119312525310611/d46722d8k.htm)) |
| Q2 2026 | [Mirum Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | scheduled | "-Phase 2b VISTAS topline data expected second quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/mirm-20251104xexx991.htm)) |
| Q2 2026 | [Brelovitug interim data readout](https://sec-api.dev/pdufa/brelovitug) | MIRM |  | scheduled | "•Bluejay Therapeutics' AZURE-1 study in HDV interim data expected in Q2 2026 and topline Phase 3 data expected in H2 2026 assuming closing of proposed acquisition" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/mirm-20260112xexx991.htm)) |
| Q2 2026 | [Mirum Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | scheduled | "-VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000030/mirm-20250507xexx991.htm)) |
| May 6, 2026 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/mirm-20260506xexx991.htm)) |
| 2H 2026 | [Brelovitug NDA/BLA submission](https://sec-api.dev/pdufa/brelovitug) | MIRM |  | scheduled | "Topline data from the program are expected in the second half of 2026 with a potential BLA submission and launch in" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000119312526022582/d35336dex991.htm)) |
| July 29, 2026 | [LIVMARLI® (maralixibat) primary completion](https://sec-api.dev/pdufa/maralixibat) | MIRM | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | completed | "NCT06553768 (Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-29 (ACTUAL); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06553768)) |
| August 2026 | [Brelovitug primary completion](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | delayed | "NCT07298330 (A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07298330)) |
| August 5, 2026 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm)) |
| September 25, 2026 | [ATEBRIOZ® (zilurgisertib) FDA approval](https://sec-api.dev/pdufa/zilurgisertib) | MIRM |  | completed, approved | "Atebrioz \| zilurgisertib \| 9/25/2026 \| To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 26, 2026 | [ATEBRIOZ® (zilurgisertib) PDUFA date](https://sec-api.dev/pdufa/zilurgisertib) | MIRM |  | completed, approved | "•Presented positive pivotal Phase 2 results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva (FOP) at ENDO 2026; Prescription Drug User Fee Act (PDUFA) target action date for the zilurgisertib NDA is September 26, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm)) |
| Q4 2026 | [Mirum Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | scheduled | "We completed enrollment of the EXPAND study in the first half of 2026 with topline data expected in the fourth quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000045/mirm-20260630.htm)) |
| Q4 2026 | [Pruritus topline data readout](https://sec-api.dev/pdufa/pruritus) | MIRM |  | scheduled | "BID, twice daily PBO Patients with Cholestatic Pruritus n~45 Topline Data Expected Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/mirumupdatedcorporatepre.htm)) |
| Q4 2026 | [Brelovitug topline data readout](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "Brelovitug is currently being evaluated in the global AZURE clinical program with topline results from the AZURE-1 and AZURE-4 registration-enabling clinical trials expected in the third and fourth quarter of 2026, respectively, and top-line results from the AZURE-2 and AZURE-3 registration-enabling clinical trials expected by the first half of 2028." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000045/mirm-20260630.htm)) |
| Q4 2026 | [LIVMARLI® (maralixibat) topline data readout](https://sec-api.dev/pdufa/maralixibat) | MIRM |  | scheduled | "•LIVMARLI EXPAND Phase 3 study in cholestatic pruritus due to additional rare cholestatic conditions topline results expected in Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm)) |
| Q4 2026 | [Mirum Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | scheduled | "Topline results from the Phase 3 AZURE-4 study, the second of the two pivotal studies supporting the U.S. registration package, are expected in the fourth quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000049/mirm-20260925.htm)) |
| November 3, 2026 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000061/mirm-20261103xexx991.htm)) |
| Q1 2027 | [Volixibat topline data readout](https://sec-api.dev/pdufa/volixibat) | MIRM | PBC and recently completed enrollment | scheduled | "The Company also now expects topline data from its VANTAGE Phase 2b study of volixibat in primary biliary cholangitis ("PBC") in the first quarter of 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1759425/000119312526202609/d150234d8k.htm)) |
| 1H 2027 | [ATEBRIOZ® (zilurgisertib) NDA/BLA submission](https://sec-api.dev/pdufa/zilurgisertib) | MIRM |  | scheduled | "•ATEBRIOZ (zilurgisertib) sNDA submission to expand the indication to pediatric patients aged 6 to <12 years planned for H1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000061/mirm-20261103xexx991.htm)) |
| Q1 2027 | [Mirum Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | scheduled | "•Completed enrollment in the volixibat VANTAGE Phase 2b study in cholestatic pruritus due to primary biliary cholangitis (PBC); topline results expected in Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm)) |
| 2027 | [MRM-3379 topline data readout](https://sec-api.dev/pdufa/mrm-3379) | MIRM |  | scheduled | "•MRM-3379 BLOOM Phase 2 in fragile X syndrome (FXS) topline data expected in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000061/mirm-20261103xexx991.htm)) |
| 1H 2027 | [Volixibat NDA/BLA submission](https://sec-api.dev/pdufa/volixibat) | MIRM | pruritus due to PSC | scheduled | "We expect to submit a potential NDA to the FDA in the first half of 2027 for approval of volixibat for the treatment of pruritus due to PSC based on the VISTAS study and supporting data, but regulatory authorities still may not agree with our interpretation of the safety or efficacy data from the study and may not grant approval." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000062/mirm-20260930.htm)) |
| Q1 2027 | [LIVMARLI® (maralixibat) topline data readout](https://sec-api.dev/pdufa/maralixibat) | MIRM |  | scheduled | "•VANTAGE study in primary biliary cholangitis (PBC) topline results now expected in Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/mirm-20260506xexx991.htm)) |
| January 2027 | [Volixibat primary completion](https://sec-api.dev/pdufa/volixibat) | MIRM | Primary Biliary Cholangitis; PBC | scheduled | "NCT05050136 (A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05050136)) |
| Jun to Sep 2027 | [Brelovitug topline data readout](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "NCT07200908 (A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07200908)) |
| June 2027 | [Brelovitug primary completion](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "NCT07200908 (A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07200908)) |
| 2H 2027 | [Mirum Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | scheduled | "Topline results from the Phase 3 AZURE-2 and AZURE-3 studies are expected in the second half of 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000049/mirm-20260925.htm)) |
| Aug to Nov 2027 | [Brelovitug (bjt-778) topline data readout](https://sec-api.dev/pdufa/brelovitug-bjt-778) | MIRM | Chronic Hepatitis D | scheduled | "NCT07454837 (Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07454837)) |
| August 2027 | [Brelovitug (bjt-778) primary completion](https://sec-api.dev/pdufa/brelovitug-bjt-778) | MIRM | Chronic Hepatitis D | scheduled | "NCT07454837 (Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07454837)) |
| October 2027 | [Low dose of mrm-3379 primary completion](https://sec-api.dev/pdufa/low-dose-of-mrm-3379) | MIRM | Fragile X Syndrome | scheduled | "NCT07209462 (Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07209462)) |
| Oct 2027 to Jan 2028 | [Low dose of mrm-3379 topline data readout](https://sec-api.dev/pdufa/low-dose-of-mrm-3379) | MIRM | Fragile X Syndrome | scheduled | "NCT07209462 (Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07209462)) |
| 1H 2028 | [Mirum Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | scheduled | "AZURE 2 and 3, Phase 3 topline data expected H1 2028 (EU registrational program)" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm)) |
| Jan to Apr 2029 | [LIVMARLI® (maralixibat) topline data readout](https://sec-api.dev/pdufa/maralixibat) | MIRM | Intrahepatic Cholestasis of Pregnancy | scheduled | "NCT07823127 (MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823127)) |
| January 2029 | [LIVMARLI® (maralixibat) primary completion](https://sec-api.dev/pdufa/maralixibat) | MIRM | Intrahepatic Cholestasis of Pregnancy | scheduled | "NCT07823127 (MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07823127)) |
| May 2029 | [Brelovitug primary completion](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "NCT06907290 (A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06907290)) |
| May to Aug 2029 | [Brelovitug topline data readout](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "NCT06907290 (A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06907290)) |

## Drugs

- [Brelovitug](https://sec-api.dev/pdufa/brelovitug): Chronic Hepatitis D Infection
- [Brelovitug (bjt-778)](https://sec-api.dev/pdufa/brelovitug-bjt-778): Chronic Hepatitis D
- [Chenodal (chenodal)](https://sec-api.dev/pdufa/chenodal): ctx, known
- [CTEXLI® (chenodiol)](https://sec-api.dev/pdufa/chenodiol): ctx in adults, cerebrotendinous xanthomatosis in adults
- [Low dose of mrm-3379](https://sec-api.dev/pdufa/low-dose-of-mrm-3379): Fragile X Syndrome
- [LIVMARLI® (maralixibat)](https://sec-api.dev/pdufa/maralixibat): Intrahepatic Cholestasis of Pregnancy, Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
- [MRM-3379](https://sec-api.dev/pdufa/mrm-3379): fragile-x syndrome
- [Pruritus](https://sec-api.dev/pdufa/pruritus): 
- [Volixibat](https://sec-api.dev/pdufa/volixibat): pruritus due to psc, pbc and recently completed enrollment, primary sclerosing cholangitis, Primary Biliary Cholangitis
- [ATEBRIOZ® (zilurgisertib)](https://sec-api.dev/pdufa/zilurgisertib): Fibrodysplasia Ossificans Progressiva (FOP)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mirm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MIRM catalysts: Mirum Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mirm/catalysts

```bibtex
@misc{secapidev_companies_mirm_catalysts_20261116,
  title        = {MIRM catalysts: Mirum Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mirm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mirm_catalysts_20261116","title":"MIRM catalysts: Mirum Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mirm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
